Bremelanotide

ID: bremelanotide

Aliases: PT-141, Vyleesi

Type: compound

Route/form: subcutaneous injection in approved Vyleesi product

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, label

Linked sources: 3

Broad outcomes: Cardiovascular / lipids / blood pressure, Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• melanocortin receptor agonism
• central sexual desire/arousal pathways
• MC4R/MC1R-related melanocortin activity

Optimization domains

• libido
• sexual health
• female sexual interest arousal disorder
• melanocortin
• blood pressure

Research basis

• Approved bremelanotide has label support and phase 3 trials for acquired generalized hypoactive sexual desire disorder in premenopausal women.

Limits, risks, and missing evidence

• Approved indication is specific and does not validate broad male libido, erectile, mood, or recreational use claims.
• Nausea, flushing, injection reactions, transient blood-pressure increases, heart-rate decreases, and hyperpigmentation warnings matter.

Risk flags

• prescription
• blood pressure
• nausea
• hyperpigmentation
• injection site reactions
• medical supervision

Linked papers, labels, and reviews

1. DailyMed label: VYLEESI bremelanotide injection
   label / dailymed_vyleesi_label
   Bremelanotide label context for acquired generalized HSDD in premenopausal women, subcutaneous route, nausea, blood-pressure, and hyperpigmentation warnings.
2. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials
   human_rct / pubmed_bremelanotide_reconnect_phase3_2019
   RECONNECT phase 3 randomized trials in premenopausal women with HSDD.
3. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
   human_rct / pubmed_bremelanotide_dose_finding_2016
   Phase 2b dose-finding trial with subcutaneous bremelanotide.